Ultragenyx Pharmaceutical RARE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $669.71M-0.4% | $672.71M+6.8% | $630.08M+3.4% | $609.64M+3.3% | $590.17M+5.4% | ||
| $771.23M+2.8% | $750.23M+2.1% | $734.85M+6.7% | $688.75M+0.5% | $685.51M-1.8% | ||
| $349.2M+0.3% | $348.2M+1.8% | $342.15M+1.9% | $335.88M+1.8% | $329.84M+2.8% | ||
| -$561.06M-4.9% | -$535.06M+1.7% | -$544.08M-7.7% | -$505.18M+1.6% | -$513.65M+4.2% | ||
| -83.8%-4.2pp | -79.5%+6.8pp | -86.4%-3.5pp | -82.9%+4.2pp | -87%+8.7pp | ||
| $24.17M-4.0% | $25.17M-12.3% | $28.7M-14.5% | $33.57M-4.6% | $35.18M-4.9% | ||
| -$605.23M-6.0% | -$571.23M+0.9% | -$576.36M-8.7% | -$530.04M+3.1% | -$546.77M+3.6% | ||
| $3.69M0.0% | $3.69M+15.2% | $3.2M+21.6% | $2.63M+3.5% | $2.55M+27.3% | ||
| -$608.92M-5.9% | -$574.92M+0.8% | -$579.57M-8.8% | -$532.67M+3.0% | -$549.32M+3.5% | ||
| -90.9%-5.5pp | -85.5%+6.5pp | -92%-4.6pp | -87.4%+5.7pp | -93.1%+8.5pp | ||
| -$6.10-4.6% | -$5.83+1.7% | -$5.93-7.4% | -$5.52+6.0% | -$5.87+7.3% | ||
| -$6.10-4.6% | -$5.83+1.7% | -$5.93-7.4% | -$5.52+6.0% | -$5.87+7.3% | ||
| 397.4M+1.1% | 393.1M+2.1% | 385M+1.1% | 380.8M+3.2% | 368.9M+3.4% | ||
| 397.4M+1.1% | 393.1M+2.1% | 385M+1.1% | 380.8M+3.2% | 368.9M+3.4% | ||
| $110.34M+0.9% | $109.34M+12.5% | $97.16M+7.7% | $90.19M+1.9% | $88.47M+14.9% | ||
| $1.23B+1.9% | $1.21B+2.9% | $1.17B+5.3% | $1.11B+1.0% | $1.1B+0.7% | ||
| $68.66M+11.4% | $61.66M+6.9% | $57.67M-2.6% | $59.23M-3.1% | $61.15M-2.9% | ||
| $669.71M-0.4% | $672.71M+6.8% | $630.08M+3.4% | $609.64M+3.3% | $590.17M+5.4% | ||
| -$561.06M-4.9% | -$535.06M+1.7% | -$544.08M-7.7% | -$505.18M+1.6% | -$513.65M+4.2% | ||
| -$527.06M-5.4% | -$500.06M+1.6% | -$508.33M-8.3% | -$469.28M+1.7% | -$477.5M+4.5% | ||
| -$527.06M-5.4% | -$500.06M+1.6% | -$508.33M-8.3% | -$469.28M+1.7% | -$477.5M+4.5% | ||
| -78.7%-4.4pp | -74.3%+6.3pp | -80.7%-3.7pp | -77%+3.9pp | -80.9%+8.4pp | ||
| -$561.06M-4.9% | -$535.06M+1.7% | -$544.08M-7.7% | -$505.18M+1.6% | -$513.65M+4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's profit margins?
- Gross margin is 97.2% and operating margin is -83.8%, with a -90.9% net margin.
- Where does Ultragenyx Pharmaceutical's income statement data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.